SynCardia Systems, a privately held developer of biomechanical cardiac replacement and assist devices, announced today that the U.S. Food and Drug Administration (FDA) approved its CardioWest™ temporary Total Artificial Heart... read more
SynCardia Systems, Inc., a privately held developer of biomechanical cardiac replacement and assist devices, today announced the appointment of Carole E. Marcot... read more
SynCardia Systems, Inc., a privately held developer of biomechanical cardiac replacement and assist devices, today announced that the August 26 issue of the New England Journal of Medicine features the results of the multi-center study... read more
SynCardia Systems, Inc., a privately held developer of biomechanical cardiac replacement and assist devices, today announced that a single center nine year heart study has been published... read more
SynCardia Systems, Inc., a privately held developer of biomechanical cardiac replacement and assist devices, today announced the appointment of Michael J. Quinn to its Board of Directors... read more
SynCardia Systems, Inc., a privately held developer of biomechanical cardiac replacement and assist devices, announced today the completion of a Series B financing of $3.7 million... read more
SynCardia Systems, Inc., a privately held developer of biomechanical cardiac replacement and assist devices, announced today the appointment of Rodger G. Ford to its Board of Directors... read more
SynCardia Systems, a privately held developer of biomechanical cardiac replacement and assist devices, announced today that the U.S. Food and Drug Administration’s (FDA) Circulatory Systems Devices Panel met yesterday and recommended that the CardioWest™ temporary Total Artificial Heart (TAH-t) be approved, with conditions, by the FDA... read more
SynCardia Systems, Inc., a privately held developer of biomechanical cardiac replacement and assist devices, announced today that the U.S. Food and Drug Administration’s (FDA) Circulatory Systems Devices Panel will discuss... read more
